Clinical Trials Details

Relapsed, Indolent or Aggressive Non-Hodgkins Lymphoma (NHL)

BAY 80-6946, PI3K inhibitor in patients with relapsed, indolent or aggressive Non-Hodgkin's Lymphoma (NHL)

Objective

• Follicular Lymphoma grade 1,2,3a
• Small lymphocytic lymphoma
• Lymphoplasmacytoid lymphoma/Waldenstrom Macroglobulinemia
• Marginal zone lymphoma

Relapsed or refractory after equal or greater than 2 prior lines of therapy.  Patients must have received Rituxan.

IRB Protocol Number

BAY 80-6946

Principal Investigator(s)

Brock Whittenberger, MD

Sponsor(s)

Bayer Healthcare

Contact

Linda Allen, RN OCN at 406-435-7481
or lallen@billingsclinic.org